Connect Biopharma Holdings Limited

Equities

CNTB

US2075231017

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 25/05/2024 am IST			5-day change	1st Jan Change
1.76 ^USD	-2.22%		-1.12%	+49.15%

17/04	Sector Update: Health Care Stocks Retreating Late Afternoon	MT
17/04	Sector Update: Health Care	MT

Connect Biopharma Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023

September 13, 2023 at 02:18 am IST

Connect Biopharma Holdings Limited reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was CNY 211.96 million compared to CNY 401.28 million a year ago. Basic loss per share from continuing operations was CNY 3.9 compared to CNY 7.3 a year ago.

Latest news about Connect Biopharma Holdings Limited

Sector Update: Health Care Stocks Retreating Late Afternoon	18/04	MT
Sector Update: Health Care	18/04	MT
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	18/04	MT
HC Wainwright Adjusts Price Target on Connect Biopharma Holdings to $8 From $7, Maintains Buy Rating	17/04	MT
Connect Biopharma Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%	09/04	DJ
ADRs Advance; Connect Biopharma Climbs 19%	06/04	DJ
ADRs Close Lower; Moatable Inc. Declines 33.3%	05/04	DJ
ADRs End Higher; Connect Biopharma Climbs 26%	02/04	DJ
ADRs End Higher; Connect Biopharma Holdings Climbs 21%	28/03	DJ
HC Wainwright Starts Coverage on Connect Biopharma With Buy Rating, $7 Price Target	04/03	MT
ADRs End Flat; Tuniu Climbs 16%	24/02	DJ
Connect Biopharma Holdings Limited Appoints James Huang to Board of Directors	13/02	CI
ADRs End With Gains; TC BioPharm Climbs 38%	10/02	DJ
Transcript : Connect Biopharma Holdings Limited - Special Call	12/12
Connect Biopharma Holdings Limited Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-To-Severe Persistent Asthma	12/12	CI
Simcere Signs Commercialization Deal for Sale of Dermatitis Treatment in China	22/11	MT
ADRs Slump, Connect Biopharma Holdings Ltd. Declines 38.8%	22/11	DJ
Transcript : Connect Biopharma Holdings Limited - Special Call	21/11
Simcere Pharmaceutical Group Limited Enters into an Exclusive License and Collaboration Agreement with Connect Biopharma Hongkong Limited in Relation to Rademikibart	21/11	CI
Connect Biopharma Releases 'Positive' Stage 2 Atopic Dermatitis Trial Results; Unveils Licensing Deal; Shares Surge Premarket	21/11	MT
Connect Biopharma Holdings Limited Appoints Kan Chen as Member of Compensation Committee	21/11	CI
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-To-Severe Atopic Dermatitis	21/11	CI
ADRs Advance; Trivago N.V. Climbs 86.6%	03/11	DJ
ADRs Advance, Cellectis S.A. Climbs 172.2%	02/11	DJ

Chart Connect Biopharma Holdings Limited

Duration

Period

Chart Connect Biopharma Holdings Limited

More charts

Company Profile

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company focused on improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. It is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4RÎ±) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4RÎ±, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. Its second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). Icanbelimod is an orally available, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells.

Sector

Biotechnology & Medical Research

Calendar

10/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.76 USD

Average target price

7 USD

Spread / Average Target

+297.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CONNECT BIOPHARMA HOLDINGS LIMITED	+49.15%	96.98M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs